Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    YXT.com

    MCap

    USD127m

    Last close

    USD23.43

    ▲ 20.23 (632.19%)

    Northern Data Group

    MCap

    EUR486m

    Last close

    EUR7.56

    ▲ 2.33 (44.59%)

    Bodycote

    MCap

    GBP1,572m

    Last close

    GBP9.23

    ▲ 173.00 (23.07%)

  • Sectors

    Sectors

  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sparks commentary

Healthcare

Sparks

Summit’s (NASDAQ: SMMT) ivonescimab beats Keytruda
Published by Arron Aatkar, PhD

Summit Therapeutics has announced that its bispecific antibody, ivonescimab, demonstrated notable benefit over Keytruda in non-small cell lung cancer, highlighting potential as a new standard of care. The data showed that ivonescimab extended progression-free survival (PFS, the time patients lived without tumour progression) by 5.3 months versus Merck’s blockbuster immune checkpoint inhibitor (>$25bn in sales in 2023), translating to a statistically significant 49% reduction in the risk of cancer progression or death.

While Summit announced top-line results for the Phase III HARMONi-2 trial in late-May 2024, the first presentation of data came at the World Conference on Lung Cancer (7–10 September 2024). It is worth noting that HARMONi-2 was conducted entirely in China, and despite the encouraging results, they will not support a US approval. Summit is running other large head-to-head Phase III studies with results expected from late-2025, which, if positive, could support a US approval.

 

Next Sparks Commentary in this sector >

Latest

Industrials | Comment

Morgan Advanced Materials (LSE: MGAM) – Phasing lifts H126 margin

TMT | Comment

Pathos Communications (AIM: NEWS) – Record July revenue supports H126 trading update

Industrials | Comment

PVA TePla (FRA: PVE) – Q226 results

Industrials | Comment

Metlen Energy & Metals (LSE: MTLN; ATHEX: MYTIL) – Strong H1; FY26 and medium-term guidance confirmed

Consumer | Comment

PZ Cussons (LSE: PZC) – FY26 results
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.